Genome-wide analysis of copy number variation identifies candidate gene loci associated with the progression of non-alcoholic fatty liver disease

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Zain, Shamsul Mohd ^a   Mohamed, Rosmawati ^a   Cooper, David N ^b   Razali, Rozaimi ^a   Rampal, Sanjay ^a   Mahadeva, Sanjiv ^a   Chan, Wah Kheong ^a   Anwar, Arif ^a   Rosli, Nurul Shielawati Mohamed ^a   Mahfudz, Anis Shafina ^c   Cheah, Phaik Leng ^d   Basu, Roma Choudhury ^e   Mohamed, Zahurin ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^d Faculty of Medicine   (Malaysia)

^e UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

EXPORTIN 4; NUCLEAR PROTEIN; PHOSPHODIESTERASE I; UNCLASSIFIED DRUG; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1; KARYOPHERIN; XPO4 PROTEIN, HUMAN;

ADULT; ARTICLE; CELL DEATH; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; DISEASE COURSE; FATTY LIVER; FEMALE; GENE IDENTIFICATION; GENE LOCUS; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MALE; NONALCOHOLIC FATTY LIVER; ONCOGENE; PDE1B GENE; PILOT STUDY; XPO4 GENE; GENETICS; IN VITRO STUDY; MIDDLE AGED; PROCEDURES;

COMPARATIVE GENOMIC HYBRIDIZATION; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 1; DNA COPY NUMBER VARIATIONS; FEMALE; HUMANS; IN VITRO TECHNIQUES; KARYOPHERINS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84899755032     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095604     Document Type: Article

References (53)

1. Fabbrini E, Sullivan S, Klein S (2010) Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51: 679-689.
2. Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L (2009) Molecular mechanisms involved in NAFLD progression. J Mol Med (Berl) 87: 679-695.
3. Jou J, Choi SS, Diehl AM (2008) Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 28: 370-379.
4. Farrell GC, van Rooyen D, Gan L, Chitturi S (2012) NASH is an inflammatory disorder: pathogenic, prognostic and therapeutic implications. Gut Liver 6: 149-171.
5. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, et al. (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142: 1592-1609.
6. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, et al. (2006) Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44: 865-873. (Pubitemid 46489550)
7. Hernaez R (2012) Genetic factors associated with the presence and progression of nonalcoholic fatty liver disease: a narrative review. Gastroenterol Hepatol 35: 32-41.
8. Farrell GC, Wong VW, Chitturi S (2013) NAFLD in Asia-as common and important as in the West. Nat Rev Gastroenterol Hepatol 10: 307-318.
9. Vernon G, Baranova A, Younossi ZM (2011) Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34: 274-285.
10. Schwimmer JB, Celedon MA, Lavine JE, Salem R, Campbell N, et al. (2009) Heritability of nonalcoholic fatty liver disease. Gastroenterology 136: 1585-1592.
11. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, et al. (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40: 1461-1465.
12. Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, et al. (2011) Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 7: e1001324.
13. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, et al. (2004) Detection of large-scale variation in the human genome. Nat Genet 36: 949-951. (Pubitemid 39167488)
14. Sebat J, Lakshmi B, Troge J, Alexander J, Young J, et al. (2004) Large-scale copy number polymorphism in the human genome. Science 305: 525-528. (Pubitemid 38971344)
15. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, et al. (2006) Global variation in copy number in the human genome. Nature 444: 444-454. (Pubitemid 44809057)
16. Pinto D, Marshall C, Feuk L, Scherer SW (2007) Copy-number variation in control population cohorts. Hum Mol Genet 16 Spec No.2: R168-173.
17. Stone JL, O'Donovan MC, Gurling H, Kirov GK, Blackwood DH, et al. (2008) Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 455: 237-241.
18. Pinto D, Pagnamenta AT, Klei L, Anney R, Merico D, et al. (2010) Functional impact of global rare copy number variation in autism spectrum disorders. Nature 466: 368-372.
19. Lionel AC, Crosbie J, Barbosa N, Goodale T, Thiruvahindrapuram B, et al. (2011) Rare copy number variation discovery and cross-disorder comparisons identify risk genes for ADHD. Sci Transl Med 3: 95ra75.
20. Clarke AJ, Cooper DN (2010) GWAS: heritability missing in action? Eur J Hum Genet 18: 859-861.
21. Bae JS, Cheong HS, Kim JH, Park BL, Park TJ, et al. (2011) The genetic effect of copy number variations on the risk of type 2 diabetes in a Korean population. PLoS One 6: e19091.
22. Wheeler E, Huang N, Bochukova EG, Keogh JM, Lindsay S, et al. (2013) Genome-wide SNP and CNV analysis identifies common and low-frequency variants associated with severe early-onset obesity. Nat Genet 45: 513-517.
23. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA (2011) Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 53: 810-820.
24. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321. (Pubitemid 40770284)
25. Ruhl CE, Everhart JE (2005) Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin Gastroenterol Hepatol 3: 1260-1268. (Pubitemid 41797679)
26. Sanyal AJ (2002) AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 123: 1705-1725. (Pubitemid 35231670)
27. Venkatraman ES, Olshen AB (2007) A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 23: 657-663. (Pubitemid 46554715)
28. Nguyen DQ, Webber C, Hehir-Kwa J, Pfundt R, Veltman J, et al. (2008) Reduced purifying selection prevails over positive selection in human copy number variant evolution. Genome Res 18: 1711-1723.
29. Chang ML, Yeh CT, Chen JC, Huang CC, Lin SM, et al. (2008) Altered expression patterns of lipid metabolism genes in an animal model of HCV core-related, nonobese, modest hepatic steatosis. BMC Genomics 9: 109.
30. Nagashima S, Yagyu H, Takahashi N, Kurashina T, Takahashi M, et al. (2011) Depot-specific expression of lipolytic genes in human adipose tissues-association among CES1 expression, triglyceride lipase activity and adiposity. J Atheroscler Thromb 18: 190-199.
31. Caldwell S, Argo C (2010) The natural history of non-alcoholic fatty liver disease. Dig Dis 28: 162-168.
32. Herzog H (2003) Neuropeptide Y and energy homeostasis: insights from Y receptor knockout models. Eur J Pharmacol 480: 21-29. (Pubitemid 37410358)
33. Bloomfeld RS, Graham BG, Schiffman SS, Killenberg PG (1999) Alterations of chemosensory function in end-stage liver disease. Physiol Behav 66: 203-207. (Pubitemid 29206510)
34. Glusman G, Yanai I, Rubin I, Lancet D (2001) The complete human olfactory subgenome. Genome Res 11: 685-702. (Pubitemid 32447857)
35. Liu N, Crasto CJ, Ma M (2007) Integrated olfactory receptor and microarray gene expression databases. BMC Bioinformatics 8: 231.
36. Dong D, Jin K, Wu X, Zhong Y (2012) CRDB: database of chemosensory receptor gene families in vertebrate. PLoS One 7: e31540.
37. Quiroga AD, Li L, Trotzmuller M, Nelson R, Proctor SD, et al. (2012) Deficiency of carboxylesterase 1/esterase-x results in obesity, hepatic steatosis, and hyperlipidemia. Hepatology 56: 2188-2198.
38. Ashla AA, Hoshikawa Y, Tsuchiya H, Hashiguchi K, Enjoji M, et al. (2010) Genetic analysis of expression profile involved in retinoid metabolism in nonalcoholic fatty liver disease. Hepatol Res 40: 594-604.
39. Peters U, North KE, Sethupathy P, Buyske S, Haessler J, et al. (2013) A systematic mapping approach of 16q12.2/FTO and BMI in more than 20, 000 African Americans narrows in on the underlying functional variation: results from the Population Architecture using Genomics and Epidemiology (PAGE) Study. PLoS Genet 9: e1003171.
40. Na K, Jeong SK, Lee MJ, Cho SY, Kim SA, et al. (2013) Human liver carboxylesterase 1 outperforms alpha-fetoprotein as biomarker to discriminate hepatocellular carcinoma from other liver diseases in Korean patients. Int J Cancer 133: 408-415.
41. Almon RR, Dubois DC, Sukumaran S, Wang X, Xue B, et al. (2012) Effects of high fat feeding on liver gene expression in diabetic goto-kakizaki rats. Gene Regul Syst Bio 6: 151-168.
42. Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, et al. (2008) An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135: 852-864.
43. Liang XT, Pan K, Chen MS, Li JJ, Wang H, et al. (2011) Decreased expression of XPO4 is associated with poor prognosis in hepatocellular carcinoma. J Gastroenterol Hepatol 26: 544-549.
44. Zhang H, Wei S, Ning S, Jie Y, Ru Y, et al. (2013) Evaluation of TGFbeta, XPO4, elF5A2 and ANGPTL4 as biomarkers in HCC. Exp Ther Med 5: 119-127.
45. Lee S, Kim S (2007) Gene regulations in HBV-related liver cirrhosis closely correlate with disease severity. J Biochem Mol Biol 40: 814-824. (Pubitemid 47572850)
46. Lin S, Shi YC, Yulyaningsih E, Aljanova A, Zhang L, et al. (2009) Critical role of arcuate Y4 receptors and the melanocortin system in pancreatic polypeptide-induced reduction in food intake in mice. PLoS One 4: e8488.
47. Liu YL, Semjonous NM, Murphy KG, Ghatei MA, Bloom SR (2008) The effects of pancreatic polypeptide on locomotor activity and food intake in mice. Int J Obes (Lond) 32: 1712-1715.
48. Zhang L, Bijker MS, Herzog H (2011) The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer. Pharmacol Ther 131: 91-113.
49. Zain SM, Mohamed R, Mahadeva S, Cheah PL, Rampal S, et al. (2012) A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease. Hum Genet 131: 1145-1152.
50. Zain SM, Mohamed Z, Mahadeva S, Rampal S, Basu RC, et al. (2013) Susceptibility and gene interaction study of the angiotensin II type 1 receptor (AGTR1) gene polymorphisms with non-alcoholic fatty liver disease in a multiethnic population. PLoS One 8: e58538.
51. Royo F, Zabala A, Paz N, Acquadro F, Echevarria JJ, et al. (2013) Genome-wide analysis of DNA copy number changes in liver steatosis. Br J Med Med Res 3: 1773-1785.
52. Curtis C, Lynch AG, Dunning MJ, Spiteri I, Marioni JC, et al. (2009) The pitfalls of platform comparison: DNA copy number array technologies assessed. BMC Genomics 10: 588.
53. Rappaport N, Nativ N, Stelzer G, Twik M, Guan-Golan Y, et al. (2013) MalaCards: an integrated compendium for diseases and their annotation. Database (Oxford) 2013: bat018.